Replimune Group Inc at JPMorgan Healthcare Conference Transcript
&-
Let's get started here and welcome everyone to the 42nd Annual JPMorgan Healthcare Conference. My name is [Anupam Rama], I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Priyanka Grover, [Lorea Hall, and Malcolm Kuno]. Our next presenting company is Replimune presenting on behalf of the company, we have Philip Astley-Sparke. Philip?
Thank you, Anupam. Recognizing revenue and is an industry leader in oncolytic immunotherapy, we're progressing to asset RP1 and RP2 RP1. We plan to establish a broad skin cancer franchise in this regard, our foundational study is in PD-1 failed melanoma, where in 140 patient registrational cohort, we have shown benefit in approximately one in three patients by way of durable response and plan to file a BLA by the end of this year.
We've also generated data in multiple non-melanoma skin cancers, principally in cutaneous squamous cell carcinoma patients late
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
